Publications by authors named "Douglas B Tang"
Article Synopsis
- RTS,S/AS02A is the only malaria vaccine shown to provide some level of protection in field trials, and researchers are exploring new formulations to enhance its effectiveness.
- In a study with rhesus macaques, various RTS,S/adjuvant formulations were tested for safety and immune response, with RTS,S/AS01B showing the best results in generating antibodies and T-cell responses.
- The findings suggest that RTS,S/AS01B is a safer and more effective option than the current standard formulation, with further clinical trials planned to assess its potential against malaria infection.
We assessed the prophylactic efficacy of azithromycin (250 mg/day) against malaria in 276 adults in western Thailand in a randomized, double-blind, placebo-controlled trial. After antimalarial suppressive treatment, volunteers were randomized in a 2:1 ratio to either the azithromycin or placebo, respectively. Study medication was given for an average of 74 days.
View Article and Find Full Text PDFBackground: Tafenoquine is an 8-aminoquinoline developed as a more effective replacement for primaquine. In a previous dose-ranging study in Thailand, 3 tafenoquine regimens with total doses ranging from 500 mg to 3000 mg prevented relapse of Plasmodium vivax malaria in most patients when administered 2 days after receipt of a blood schizonticidal dose of chloroquine.
Methods: To improve convenience and to begin comparison of tafenoquine with primaquine, 80 patients with P.
We assessed monthly doses of tafenoquine for preventing Plasmodium vivax and multidrug-resistant P. falciparum malaria. In a randomized, double-blind, placebo-controlled study, 205 Thai soldiers received either a loading dose of tafenoquine 400 mg (base) daily for 3 days, followed by single monthly 400-mg doses (n = 104), or placebo (n = 101), for up to 5 consecutive months.
View Article and Find Full Text PDF